Azabicyclo Compounds

"Azabicyclo Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Bicyclic bridged compounds that contain a nitrogen which has three bonds. The nomenclature indicates the number of atoms in each path around the rings, such as [2.2.2] for three equal length paths. Some members are TROPANES and BETA LACTAMS.

Descriptor ID	D053961
MeSH Number(s)	D02.145.074 D03.605.084.500
Concept/Terms	Azabicyclo Compounds Azabicyclo Compounds Azabicyclo(5.2.2)Undecanes Azabicyclo(5.2.2)Undecanes Azabicyclo(3.3.1)Nonanes Azabicyclo(3.3.1)Nonanes Azabicyclo(4.3.0)Nonanes Azabicyclo(4.3.0)Nonanes Azabicyclo(1.1.0)Butanes Azabicyclo(1.1.0)Butanes Azabicyclo(2.2.2)Octanes Azabicyclo(2.2.2)Octanes

Below are MeSH descriptors whose meaning is more general than "Azabicyclo Compounds".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Aza Compounds [D02.145]
Azabicyclo Compounds [D02.145.074]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, Bridged-Ring [D03.605]
Bridged Bicyclo Compounds, Heterocyclic [D03.605.084]
Azabicyclo Compounds [D03.605.084.500]

Below are MeSH descriptors whose meaning is related to "Azabicyclo Compounds".

Below are MeSH descriptors whose meaning is more specific than "Azabicyclo Compounds".

Azabicyclo Compounds
Granisetron
Tropanes

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Azabicyclo Compounds" by people in this website by year, and whether "Azabicyclo Compounds" was a major or minor topic of these publications.

Bar chart showing 52 publications over 12 distinct years, with a maximum of 11 publications in 2023

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2010	2	0	2
2015	2	0	2
2016	4	0	4
2017	3	0	3
2018	8	1	9
2019	5	1	6
2020	2	1	3
2021	2	4	6
2022	0	4	4
2023	1	10	11
2024	0	1	1
2025	1	0	1

Below are the most recent publications written about "Azabicyclo Compounds" by people in Profiles.

DeRyke CA, Wise MG, Bauer KA, Siddiqui F, Young K, Motyl MR, Sahm DF. Antimicrobial Activity of Imipenem/Relebactam and Comparator Agents Against Gram-Negative Isolates Collected From Pediatric Patients: SMART 2018-2022 Global Surveillance. J Pediatric Infect Dis Soc. 2025 Jan 20; 14(1).

View in: PubMed
Karlowsky JA, Lob SH, Hawser SP, Kothari N, Siddiqui F, Alekseeva I, DeRyke CA, Young K, Motyl MR, Sahm DF. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy-SMART 2017-2021. Eur J Clin Microbiol Infect Dis. 2024 Jul; 43(7):1343-1348.

View in: PubMed
Wise MG, Karlowsky JA, Chen WT, Siddiqui F, Young K, Motyl MR, Sahm DF. Susceptibility of gram-negative isolates collected in Taiwan to imipenem/relebactam and comparator agents - SMART 2018-2021. J Formos Med Assoc. 2024 Mar; 123(3):400-407.

View in: PubMed
Wise MG, Karlowsky JA, Hackel MA, Harti MA, Ntshole BME, Njagua EN, Oladele R, Samuel C, Khan S, Wadula J, Lowman W, Lembede BW, Sahm DF. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from sub-Saharan Africa: ATLAS Global Surveillance Program 2017-2021. J Glob Antimicrob Resist. 2023 12; 35:93-100.

View in: PubMed
Wise MG, Karlowsky JA, Mohamed N, Kamat S, Sahm DF. In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021. Eur J Clin Microbiol Infect Dis. 2023 Sep; 42(9):1135-1143.

View in: PubMed
Gales AC, Stone G, Sahm DF, Wise MG, Utt E. Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017-2019. J Antimicrob Chemother. 2023 07 05; 78(7):1606-1615.

View in: PubMed
Karlowsky JA, Lob SH, Chen WT, DeRyke CA, Siddiqui F, Young K, Motyl MR, Sahm DF. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020. Int J Antimicrob Agents. 2023 Sep; 62(3):106900.

View in: PubMed
Wise MG, Karlowsky JA, Hackel MA, Takemura M, Yamano Y, Echols R, Sahm DF. In Vitro Activity of Cefiderocol Against Meropenem-Nonsusceptible Gram-Negative Bacilli with Defined ?-Lactamase Carriage: SIDERO-WT Surveillance Studies, 2014-2019. Microb Drug Resist. 2023 Aug; 29(8):360-370.

View in: PubMed
Karlowsky JA, Lob SH, Siddiqui F, Pavia J, DeRyke CA, Young K, Motyl MR, Sahm DF. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018?2020. Braz J Infect Dis. 2023 May-Jun; 27(3):102775.

View in: PubMed
Wise MG, Karlowsky JA, Lemos-Luengas EV, Valdez RR, Sahm DF. Epidemiology and in vitro activity of ceftazidime-avibactam and comparator agents against multidrug-resistant isolates of Enterobacterales and Pseudomonas aeruginosa collected in Latin America as part of the ATLAS surveillance program in 2015?2020. Braz J Infect Dis. 2023 May-Jun; 27(3):102759.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement